{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non-malignant+Disorders&page=26",
    "query": {
      "condition": "Non-malignant Disorders",
      "page": 26
    },
    "page_size": 10
  },
  "pagination": {
    "page": 26,
    "page_size": 10,
    "total_count": 774,
    "total_pages": 78,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non-malignant+Disorders&page=27&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non-malignant+Disorders&page=25&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-07T05:29:12.702Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00398138",
      "title": "Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Leukemia",
        "Lung Cancer",
        "Malignant Mesothelioma",
        "Myelodysplastic Syndromes",
        "Primary Peritoneal Cavity Cancer"
      ],
      "interventions": [
        {
          "name": "WT-1 analog peptide vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "incomplete Freund's adjuvant",
          "type": "BIOLOGICAL"
        },
        {
          "name": "sargramostim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "polymerase chain reaction",
          "type": "GENETIC"
        },
        {
          "name": "flow cytometry",
          "type": "OTHER"
        },
        {
          "name": "immunoenzyme technique",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "GENETIC",
        "OTHER"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 22,
      "start_date": "2006-10",
      "completion_date": "2009-06",
      "has_results": true,
      "last_update_posted_date": "2016-03-02",
      "last_synced_at": "2026-11-07T05:29:12.702Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00398138"
    },
    {
      "nct_id": "NCT00897793",
      "title": "Growth Factor Levels in the Blood of Patients Undergoing Radiation Therapy for Epithelial Cancer",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Breast Cancer",
        "Colorectal Cancer",
        "Head and Neck Cancer",
        "Lung Cancer",
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "venipuncture",
          "type": "PROCEDURE"
        },
        {
          "name": "radiation therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "RADIATION"
      ],
      "sponsor": "Vanderbilt-Ingram Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2006-01",
      "completion_date": "2010-07",
      "has_results": false,
      "last_update_posted_date": "2013-04-12",
      "last_synced_at": "2026-11-07T05:29:12.702Z",
      "location_count": 3,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00897793"
    },
    {
      "nct_id": "NCT02304458",
      "title": "Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Melanoma",
        "Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor",
        "Recurrent Hodgkin Lymphoma",
        "Recurrent Malignant Solid Neoplasm",
        "Recurrent Melanoma",
        "Recurrent Neuroblastoma",
        "Recurrent Non-Hodgkin Lymphoma",
        "Recurrent Osteosarcoma",
        "Recurrent Rhabdomyosarcoma",
        "Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor",
        "Refractory Hodgkin Lymphoma",
        "Refractory Malignant Solid Neoplasm",
        "Refractory Melanoma",
        "Refractory Neuroblastoma",
        "Refractory Non-Hodgkin Lymphoma",
        "Refractory Osteosarcoma",
        "Refractory Rhabdomyosarcoma",
        "Stage III Cutaneous Melanoma AJCC v7",
        "Stage IIIA Cutaneous Melanoma AJCC v7",
        "Stage IIIB Cutaneous Melanoma AJCC v7",
        "Stage IIIC Cutaneous Melanoma AJCC v7",
        "Stage IV Cutaneous Melanoma AJCC v6 and v7",
        "Unresectable Melanoma"
      ],
      "interventions": [
        {
          "name": "Ipilimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Months",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "12 Months to 30 Years"
      },
      "enrollment_count": 140,
      "start_date": "2015-03-30",
      "completion_date": "2023-03-31",
      "has_results": true,
      "last_update_posted_date": "2023-10-17",
      "last_synced_at": "2026-11-07T05:29:12.702Z",
      "location_count": 24,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Orange, California + 21 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02304458"
    },
    {
      "nct_id": "NCT00003887",
      "title": "Lymphocyte Infusion in Treating Patients With Relapsed Cancer After Bone Marrow or Peripheral Stem Cell Transplantation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer",
        "Chronic Myeloproliferative Disorders",
        "Gestational Trophoblastic Tumor",
        "Kidney Cancer",
        "Leukemia",
        "Lymphoma",
        "Multiple Myeloma and Plasma Cell Neoplasm",
        "Myelodysplastic Syndromes",
        "Neuroblastoma",
        "Ovarian Cancer",
        "Sarcoma",
        "Testicular Germ Cell Tumor"
      ],
      "interventions": [
        {
          "name": "peripheral blood lymphocyte therapy",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "1 Year to 70 Years"
      },
      "enrollment_count": null,
      "start_date": "1998-08",
      "completion_date": "2003-02",
      "has_results": false,
      "last_update_posted_date": "2011-11-30",
      "last_synced_at": "2026-11-07T05:29:12.702Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003887"
    },
    {
      "nct_id": "NCT06810544",
      "title": "Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Non Small Cell Lung Cancer",
        "Glioma Glioblastoma Multiforme",
        "Glioma, Malignant",
        "Solid Tumor",
        "Non-Small Cell Adenocarcinoma",
        "Lung Cancer",
        "Brain Tumor"
      ],
      "interventions": [
        {
          "name": "TNG456",
          "type": "DRUG"
        },
        {
          "name": "abemaciclib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tango Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 191,
      "start_date": "2025-03-24",
      "completion_date": "2027-09-30",
      "has_results": false,
      "last_update_posted_date": "2026-10-21",
      "last_synced_at": "2026-11-07T05:29:12.702Z",
      "location_count": 15,
      "location_summary": "Scottsdale, Arizona • Irvine, California • Los Angeles, California + 11 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06810544"
    },
    {
      "nct_id": "NCT02897765",
      "title": "A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Urinary Bladder Cancer",
        "Bladder Tumors",
        "Transitional Cell Carcinoma of the Bladder",
        "Malignant Melanoma",
        "Melanoma",
        "Skin Cancer",
        "Carcinoma, Non-Small-Cell Lung",
        "Lung Cancer"
      ],
      "interventions": [
        {
          "name": "NEO-PV-01",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Adjuvant",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "BioNTech US Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 34,
      "start_date": "2016-10",
      "completion_date": "2020-05",
      "has_results": false,
      "last_update_posted_date": "2021-02-25",
      "last_synced_at": "2026-11-07T05:29:12.702Z",
      "location_count": 9,
      "location_summary": "Duarte, California • Los Angeles, California • San Francisco, California + 4 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02897765"
    },
    {
      "nct_id": "NCT06239272",
      "title": "NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Adipocytic Neoplasm",
        "Liposarcoma",
        "Atypical Fibroxanthoma",
        "Angiomatoid Fibrous Histiocytoma",
        "Fibrosarcoma NOS",
        "Myxofibrosarcoma",
        "Angiosarcoma",
        "Osteosarcoma, Extraskeletal",
        "Dedifferentiated Liposarcoma",
        "Myxoid Liposarcoma",
        "Pleomorphic Liposarcoma",
        "Myxoid Pleomorphic Liposarcoma",
        "Low Grade Fibromyxoid Sarcoma",
        "Sclerosing Epithelioid Fibrosarcoma",
        "Malignant Tenosynovial Giant Cell Tumor of Soft Tissue",
        "Epithelioid Hemangioendothelioma",
        "Glomus Tumor",
        "Inflammatory Leiomyosarcoma",
        "Leiomyosarcoma",
        "Ossifying Fibromyxoid Tumor, Malignant",
        "Myoepithelioma",
        "Synovial Sarcoma",
        "Epithelioid Sarcoma",
        "Perineurioma, Malignant",
        "Clear Cell Sarcoma",
        "Extraskeletal Myxoid Chondrosarcoma",
        "Granular Cell Tumor, Malignant",
        "Melanotic Malignant Nerve Sheath Tumor",
        "Malignant Peripheral Nerve Sheath Tumor",
        "Perivascular Epithelioid Tumor, Malignant",
        "Intimal Sarcoma",
        "Myoepithelial Carcinoma",
        "Undifferentiated Sarcoma",
        "Pleomorphic Sarcoma, Undifferentiated",
        "Round Cell Sarcoma, Undifferentiated",
        "NTRK-Rearranged Spindle Cell Neoplasm",
        "Phosphaturic Mesenchymal Tumor, Malignant",
        "Round Cell Sarcoma",
        "Well Differentiated Liposarcoma",
        "Giant Cell Tumor of Soft Parts NOS",
        "Low Grade Myofibroblastic Sarcoma",
        "Dermatofibrosarcoma Protuberans, Fibrosarcomatous"
      ],
      "interventions": [
        {
          "name": "Surgical resection",
          "type": "PROCEDURE"
        },
        {
          "name": "Proton beam radiation therapy",
          "type": "RADIATION"
        },
        {
          "name": "Pazopanib",
          "type": "DRUG"
        },
        {
          "name": "Ifosfamide",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Selinexor",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "RADIATION",
        "DRUG"
      ],
      "sponsor": "St. Jude Children's Research Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "Up to 30 Years"
      },
      "enrollment_count": 139,
      "start_date": "2024-03-27",
      "completion_date": "2037-06",
      "has_results": false,
      "last_update_posted_date": "2026-08-03",
      "last_synced_at": "2026-11-07T05:29:12.702Z",
      "location_count": 7,
      "location_summary": "Atlanta, Georgia • Chicago, Illinois • Baton Rouge, Louisiana + 4 more",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Baton Rouge",
          "state": "Louisiana"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06239272"
    },
    {
      "nct_id": "NCT00096265",
      "title": "Radiation Therapy and Stereotactic Radiosurgery With or Without Temozolomide or Erlotinib in Treating Patients With Brain Metastases Secondary to Non-Small Cell Lung Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Metastatic Malignant Neoplasm in the Brain",
        "Recurrent Non-Small Cell Lung Carcinoma",
        "Stage IV Non-Small Cell Lung Cancer AJCC v7"
      ],
      "interventions": [
        {
          "name": "3-Dimensional Conformal Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Erlotinib Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Stereotactic Radiosurgery",
          "type": "RADIATION"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 126,
      "start_date": "2004-10-06",
      "completion_date": "2012-04-01",
      "has_results": true,
      "last_update_posted_date": "2018-03-09",
      "last_synced_at": "2026-11-07T05:29:12.702Z",
      "location_count": 80,
      "location_summary": "Scottsdale, Arizona • Burbank, California • Los Angeles, California + 67 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Burbank",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Pomona",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00096265"
    },
    {
      "nct_id": "NCT02270450",
      "title": "S1316, Surgery or Non-Surgical Management in Treating Patients With Intra-Abdominal Cancer and Bowel Obstruction",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Constipation, Impaction, and Bowel Obstruction",
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "therapeutic conventional surgery",
          "type": "PROCEDURE"
        },
        {
          "name": "gastrointestinal complications management/prevention",
          "type": "PROCEDURE"
        },
        {
          "name": "quality-of-life assessment",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "SWOG Cancer Research Network",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 221,
      "start_date": "2015-03-09",
      "completion_date": "2021-10-31",
      "has_results": true,
      "last_update_posted_date": "2023-03-30",
      "last_synced_at": "2026-11-07T05:29:12.702Z",
      "location_count": 34,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 26 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02270450"
    },
    {
      "nct_id": "NCT04083183",
      "title": "Total Body Irradiation and Astatine-211-Labeled BC8-B10 Monoclonal Antibody for the Treatment of Nonmalignant Diseases",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Non-Malignant Neoplasm"
      ],
      "interventions": [
        {
          "name": "Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Lapine T-Lymphocyte Immune Globulin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Total-Body Irradiation",
          "type": "RADIATION"
        },
        {
          "name": "Hematopoietic Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Mycophenolate Mofetil",
          "type": "DRUG"
        },
        {
          "name": "Sirolimus",
          "type": "DRUG"
        },
        {
          "name": "Bone Marrow Aspiration",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "RADIATION",
        "PROCEDURE"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 40,
      "start_date": "2020-06-16",
      "completion_date": "2028-01-09",
      "has_results": false,
      "last_update_posted_date": "2026-06-17",
      "last_synced_at": "2026-11-07T05:29:12.702Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04083183"
    }
  ]
}